29.04.2014 07:35 Uhr, Quelle: Wallstreet online

PIXUVRI® Launched In UK For Adult Patients With Multiply Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

- First and Only Approved Monotherapy in the EU for this Patient Population - BIRMINGHAM, England, April 29, 2014 /PRNewswire/ - Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the launch of PIXUVRI® (pixantrone), the first …

Weiterlesen bei Wallstreet online